Department of Neurosurgery, University of Bonn, Sigmund Freud Str. 25, 53105 Bonn, Germany.
Acta Neurochir (Wien). 2011 Jan;153(1):19-25. doi: 10.1007/s00701-010-0790-7. Epub 2010 Sep 17.
The aim of this work was to retrospectively study the long-term reliability of the common consensus endocrinological criteria for the assessment of postoperative remission of acromegaly.
In 96 consecutive patients, surgical remission of acromegaly following transsphenoidal surgery was considered to be present when, without adjuvant treatment, 3 months postoperatively there was no clinical evidence of persisting disease, and, according to the common consensus criteria for acromegaly remission, GH was suppressed to < 1 μg/l during the oral glucose tolerance test (OGTT) and insulin like growth factor-1 (IGF-1) was within normal limits. The results of the second postoperative week, 3 months postoperative, and the most recent follow-up OGTT and IGF-1 measurements were used to calculate the positive and negative predictive values of the following endocrinological criteria of acromegaly remission: the common consensus criteria for acromegaly remission, GH suppression to < 1 μg/l during OGTT and IGF-1 within normal limits. Sensitive IRMA (≤ 0.3 μg/l) and RIA (≤ 32 μg/l) assays for GH and IGF-1 were used.
The surgical remission rate of acromegaly was 72.9%. At a median follow-up of 5.06 years, the recurrence rate of acromegaly was 2.08%. Overall, the common consensus criteria for acromegaly remission were the most reliable tests, with the following positive and negative predictive values at 2 weeks postoperatively, 3 months postoperatively and at the most recent follow-up: 68%, 100% and 100%, and 98%, 100% and 100%, respectively. The negative likelihood ratio confirmed that the test qualities of the common consensus criteria for acromegaly remission were superior to the other tests.
The common consensus criteria were the most reliable tests for the diagnosis of postoperative acromegaly remission. The positive and negative predictive values of the common consensus criteria for acromegaly remission increased from the second postoperative week to 3 months postoperatively, thereafter reliably indicating the long-term results of transsphenoidal surgery.
本研究旨在回顾性分析用于评估生长激素腺瘤术后缓解的通用内分泌学标准的长期可靠性。
96 例连续患者经蝶窦手术后,若术后 3 个月无持续疾病的临床证据,且根据通用缓解共识标准,生长激素(GH)在口服葡萄糖耐量试验(OGTT)中被抑制至<1μg/L,胰岛素样生长因子-1(IGF-1)处于正常范围内,可被认为术后缓解。使用第二次术后周、术后 3 个月和最近的 OGTT 和 IGF-1 测量结果来计算以下生长激素腺瘤缓解的内分泌学标准的阳性和阴性预测值:通用缓解共识标准、OGTT 中 GH 抑制至<1μg/L 和 IGF-1 正常范围内。使用敏感的免疫放射分析法(IRMA,≤0.3μg/L)和放射免疫分析法(RIA,≤32μg/L)检测 GH 和 IGF-1。
生长激素腺瘤的手术缓解率为 72.9%。在中位数为 5.06 年的随访中,生长激素腺瘤的复发率为 2.08%。总体而言,通用缓解共识标准是最可靠的检测方法,在术后 2 周、3 个月和最近的随访时,其阳性和阴性预测值分别为 68%、100%和 100%,98%、100%和 100%。阴性似然比证实,通用缓解共识标准对生长激素腺瘤的检测质量优于其他检测。
通用缓解共识标准是诊断术后生长激素腺瘤缓解的最可靠检测方法。从术后第 2 周到 3 个月,通用缓解共识标准的阳性和阴性预测值增加,此后可靠地指示经蝶窦手术的长期结果。